Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + tenofovir disoproxil fumarate + tenofovir alafenamide fumarate + interferons
- Development stage
- Preclinical
- Lead developer
- Tianjin Second People's Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This drug combination consists of three nucleos(t)ide analogues—entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide fumarate (TAF)—alongside interferons, primarily used for the management of chronic hepatitis B (CHB). Entecavir is a guanosine nucleoside analogue that inhibits Hepatitis B virus (HBV) DNA polymerase. TDF and TAF are prodrugs of tenofovir, a nucleotide analogue that also inhibits HBV reverse transcriptase; TAF is designed to deliver the active moiety more efficiently to hepatocytes with lower systemic exposure compared to TDF. Interferons are cytokines that exert both direct antiviral effects and immunomodulatory actions to enhance the host's immune response against the virus. This specific multi-drug regimen is being evaluated by Tianjin Second People's Hospital in observational clinical research to determine how comorbid conditions like fatty liver disease influence the long-term efficacy of antiviral therapy.
- Other names
- ETV + TDF + TAF + IFNEntecavir + Tenofovir Disoproxil Fumarate + Tenofovir Alafenamide Fumarate + Interferon
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on entecavir + tenofovir disoproxil fumarate + tenofovir alafenamide fumarate + interferons.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + tenofovir disoproxil fumarate + tenofovir alafenamide fumarate + interferons.